Compare Baker Hughes Co (BKR) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs BioNano Genomics Inc — how do they compare? Baker Hughes Co trades at $64.43 (market cap $63.81B), while BioNano Genomics Inc trades at $1.2 (market cap $13.77M). The key difference: Baker Hughes Co is far larger — about 4634× BioNano Genomics Inc's market cap, and Baker Hughes Co pays a 1.43% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BKR | BNGO | |
|---|---|---|
Market Cap | $63.81B | $13.77M |
Sector | Energy | Health |
52-Week High | $69.67 | $4.92 |
52-Week Low | $42.80 | $1.06 |
Enterprise Value | $64.34B | $16.38M |
Dividend Yield | 1.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.69, up 0.97% today, with strong technical and fundamental momentum. The stock shows bullish moving averages and has beaten earnings estimates for the last three quarters. Recent news includes major contracts for subsea systems and LNG technology, supporting revenue growth. Analyst consensus is strongly positive with a $73.25 price target, indicating ~13% upside from current levels.
Outlook remains favorable driven by energy infrastructure demand and operational execution, though risks include oil price volatility and integration challenges from the Chart acquisition. The stock offers growth potential with solid cash flow and margin expansion, but investors should monitor debt levels and global energy spending trends.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
